Kinetics of antibodies against adalimumab are not associated with poor outcomes in IBD

American Journal of Gastroenterology

Volumn 110, Issue 5, 2015, Pages 777-778

  Paul, S ^a   Dronne, W ^a   Roblin, X ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY;

DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADULT; BLOOD; FEMALE; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; KINETICS; MALE; RECURRENT DISEASE; TREATMENT FAILURE;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; KINETICS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84928911078     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.79     Document Type: Letter

References (3)

1. Ungar B, Chowers Y, Yavzori M et al. The temporal evolution of antidrug antibodies in patients withinflammatory bowel disease treated withinfl iximab. Gut 2014 ; 63 : 1258-64.
2. Vande Casteele N, Gils A, Singh S et al. Antibody response to infl iximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013 ; 108 : 962-71.
3. Kopylov U, Al-Taweel T, Yaghoobi M et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis 2014 ; 8 : 1632-41.